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The	 prevalence	 of	 fibroids	 has	 been	 historically	 underestimated	





ethnic	 demographics	 of	 the	 population	 studied.5	 Recent	 research	
from	 the	 United	 States	 has	 shown	 that	 fibroids	 are	 detected	 by	














tation	of	fibroids.1	 Fibroids	 are	more	 common,	 tend	 to	present	 at	 a	
younger	 age,	 are	 greater	 in	 number,	 and	 larger	 in	 size	 in	women	of	
African	ancestry	versus	white	or	Asian	women.6,9	Other	 risk	 factors	
include	obesity,	nulliparity,	hypertension,	late	menopause,	early	men-
arche,	 family	history	of	fibroids,	 and	older	 age.1	The	 impact	of	 diet,	





growth,	 and	 regression.11	Multiple	 in	vitro	 and	 in	vivo	 studies	 have	
identified	several	pathways	and	mechanisms	thought	to	be	involved	in	
the	pathogenesis	of	fibroids	including	sex	hormones,	stem	cells,	glu-
cocorticoids,	 growth	 factors,	 cytokine	 signaling,	 extracellular	matrix	
remodeling,	 and	 epigenetic	 factors.1,2,11,12	 Another	 peculiar	 charac-
teristic	of	fibroids	is	their	biological	heterogeneity	even	among	those	
within	 the	 same	woman's	 uterus,	 as	 shown	by	different	 patterns	of	
growth	over	time.13	These	considerations	highlight	the	need	for	more	
personalized	and	fibroid-	specific	treatments.
1.2 | Symptoms and patients’ experience
Up	 to	 70%	 of	 fibroids	 are	 asymptomatic	 and	 may	 be	 incidentally	





orrhea,	bladder	or	bowel	 symptoms	 (urinary	 frequency	or	 constipa-
tion),	and	sexual	dysfunction,	or	can	be	associated	with	infertility	and	
other	 poor	 obstetrical	 outcomes	 such	 as	 increased	 risk	 of	 preterm	
labor,	cesarean	delivery,	antepartum	bleeding,	fetal	malpresentation,	





Careful	 collection	 of	 medical	 history/symptoms,	 pelvic	 examina-
tion,	ultrasound,	and/or	saline-	infusion	sonogram	are	very	important	
when	planning	a	targeted	treatment	for	fibroids.14	While	ultrasound	
is	 the	most	 commonly	used	first	 line	 radiologic	evaluation	 for	uter-
ine	fibroids	and	in	most	cases	sufficient	for	their	diagnosis	(90%–99%	
sensitivity),	 it	 is	 limited	 in	 its	 ability	 to	assess	fibroid	viability/blood	
supply	which	would	be	necessary	for	counseling	a	patient	on	the	like-
lihood	of	success	of	uterine	artery	embolization	 (UAE)	and/or	mag-
netic	 resonance	 guided	 focused	ultrasound	 radiofrequency	 ablation	
(MRgFUS).14	Saline-	infusion	sonogram	is	a	very	sensitive	and	specific	
procedure	 for	 the	 detection	 of	 submucosal	 fibroids	 (98%–100%).14 







is	 the	 2011	 International	 Federation	 of	Gynecology	 and	Obstetrics	
(FIGO)	 classification	which	 describes	 eight	 classes	 of	 fibroids	while	
accounting	 for	 their	 location	and	degree	of	 intramural/intracavitary	
extension	(Fig.	1).16
2  | MANAGEMENT
The	 treatment	 of	 fibroids	 should	 not	 only	 be	 directed	 toward	
improving	 symptomatology,	 but	 also	 influenced	 by	 the	 patient's	
desire	 for	 future	 fertility,	desire	 to	 retain	 the	uterus,	 likelihood	of	
achieving	 treatment	 goals,	 and	 overall	 health	 status.	 Treatment	
options	 improve	 fibroid-	associated	 symptomatology	 by	 reducing	
the	 size	of	 the	fibroids,	 controlling	fibroid-	related	AUB,	or	 defini-
tively	curing	the	fibroids.	Available	treatments	include	medical	ther-
apies,	 interventional	 radiology,	 and	 surgical	 procedures	 (Fig.	 2).	A	
step-	up	approach	is	recommended	by	many	international	obstetri-
cal	and	gynecology	societies	when	treating	uterine	fibroids,17	which	







2.1 | Medical management of uterine fibroids  
and their symptoms
Medical	management	primarily	aims	to	reduce	the	AUB	caused	by	
fibroids.	 However,	 there	 are	 extremely	 limited	 studies	 that	 have	
specifically	 investigated	 fibroid-	related	AUB	 in	 response	 to	medi-
cal	 treatment	 as	most	data	on	AUB	certainly	 include	women	with	
fibroids	 but	 also	 women	 with	 AUB	 as	 a	 result	 of	 other	 causes.	
Available	medical	 treatments	 include	 anti-	fibrinolytic	 agents,	 non-	
steroidal	 anti-	inflammatory	 drugs	 (NSAIDs),	 combined	 hormonal	
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contraceptives,	 progesterone-	only	 treatments,	 selective	 proges-
terone	 receptor	 modulators	 (SPRMs),	 anti-	progestins,	 aromatase	
inhibitors,	 and	 gonadotropin	 releasing	 hormone	 (GnRH)	 agonists	
or	antagonists.




onists,	 and	 selective	 estrogen	 receptor	modulators.	However,	 these	








2.1.1 | Non- steroidal anti- inflammatory agents




daily)	which	 are	most	 efficacious	when	 started	a	day	or	 two	before	
the	 onset	 of	 menses	 and	 continued	 for	 the	 duration	 of	 menstrua-
tion.20	 NSAIDs	work	 by	 inhibiting	 the	 enzyme	 cyclooxygenase	 and	
lowering	the	production	of	pro-	inflammatory	prostaglandins	and	have	
been	 shown	 to	 improve	 dysmenorrhea	 and	 menorrhagia	 compared	
to placebo.20	However,	they	are	 less	effective	in	reducing	menstrual	
bleeding	 than	 tranexamic	 acid,	 combined	 hormonal	 contraceptives,	
or	 levonorgestrel	 intrauterine	 devices.20	 NSAIDs	 should	 be	 avoided	
in	women	with	 known	hypersensitivity	 to	 this	 class	 of	medications,	
active	gastric	or	peptic	ulcers,	or	renal	disease.
2.1.2 | Tranexamic acid
The	 synthetic	 lysine	 derivative,	 tranexamic	 acid,	 is	 an	 anti-	
fibrinolytic	agent	and	promoter	of	blood	clot	formation.19	It	is	one	
of	 the	 oldest	 and	 most	 globally	 available	 treatments	 of	 AUB.	 By	
preventing	fibrin	degradation	at	the	level	of	the	plasminogen	lysine	
receptor	site,	 it	 favors	pro-	coagulant	mechanisms	which	 lead	 to	a	
reduction	in	menstrual	blood	flow	and	improvement	of	symptoms.21 
Most	commonly,	it	is	administered	at	a	dose	of	two	650	mg	tablets	
orally	 three	 times	 a	 day	 for	 up	 to	 5	 days.21	 It	 is	 associated	with	
rare	 and	mild	 adverse	 effects	 including	 gastrointestinal	 and	mus-










tion,	 and	quality	of	 life	were	 found	 to	be	 improved	 in	women	who	
used	 combined	 oral	 contraceptives	 compared	 to	 placebo,	 however	
they	performed	less	well	than	progestin-	releasing	intrauterine	devices	












The	 most	 common	 progesterone-	only	 treatments	 for	 AUB	 involve	
the	use	of	oral	progestins	 (norethindrone	acetate	5	 to	10	mg	daily;	
medroxyprogesterone	 acetate	 10	mg	 daily;	 megestrol	 40	mg	 daily)	
and	 progesterone-	releasing	 IUDs.23	 Data	 on	 progestin-	only	 inject-
able	medications	 showed	high	discontinuation	 rate	due	 to	 irregular	
bleeding	 profile	 making	 them	 a	 less	 ideal	 option.17	 By	 repressing	
the	estrogenic	 stimulated	 growth	of	 the	endometrium,	 this	 class	of	
medications	consequently	decreases	blood	loss	during	menstruation.	
Some	of	 the	most	common	adverse	effects	of	 this	 class	of	medica-
tions	are	gastrointestinal	 symptoms,	 irregular	bleeding,	 acne,	breast	
tenderness,	and	mood	changes.17	Levonorgestrel-	releasing	 IUDs,	by	
acting	 locally	 on	 the	 endometrium,	 with	 minimal	 systemic	 absorp-
tion	and	adverse	effects,	cause	amenorrhea	and/or	 improvement	of	
menorrhagia	and	anemia	in	up	to	50%–60%	of	patients	with	AUB	at	




2.1.5 | Selective progesterone receptor 




(5–10	 mg	 orally	 once	 a	 day)	 has	 been	 associated	 with	 25%–50%	
fibroid	shrinkage,	and	greater	than	90%	uterine	bleeding	control	in	ini-
tial	studies	based	in	Europe	(PEARL	trial).18,24	In	Europe	and	Canada,	
this	 is	 the	 only	 SPRM	 that	 has	 been	 approved	 and	 commercialized	
as	a	3-	month	pre-	operative	adjuvant	therapy	and,	more	recently,	as	
intermittent	 treatment	of	moderate	 to	 severe	fibroid	 symptoms	 for	






Other	 SPRM	 members	 such	 as	 mifepristone,	 asoprisnil,	 vilaprisan	
and	 telapristone	 acetate	 have	 been	 investigated	 in	 phase	 2	 clinical	
trials	with	 promising	 preliminary	 results.18,25	A	main	 concern	 for	 all	
progesterone-	inhibiting	agents	is	the	potential	for	 induced	endome-
trial	 growth	 by	 the	 unopposed	 estrogens,	 which	 could	 lead	 to	 the	




2.1.6 | GnRH agonists and antagonists
Among	the	GnRH	agonists,	leuprolide	acetate	is	the	most	commonly	
used	as	a	3.75	mg	monthly	or	11.25	mg	every	3	months	 intramus-





fibroid	 growth.	GnRH	 agonists	 lead	 to	 amenorrhea	 in	most	women	
(>98%)	and	are	associated	with	a	35%–65%	decrease	 in	fibroid	size	
within	3	months	of	treatment	initiation.	In	some	cases,	this	may	allow	
for	 a	 minimally	 invasive	 surgical	 approach	 and	 may	 increase	 pre-	




of	 long-	term	use	 (>6	months).26	To	 alleviate	 some	of	 these	 adverse	
effects,	hormonal	add-	back	therapy	can	be	used	with	good	success.26
At	the	present	time,	the	use	of	GnRH	antagonists	such	as	cetro-
relix	 and	 ganirelix	 acetate	 is	 uncommon.26	 Despite	 their	 immediate	
clinical	 response,	 they	are	more	expensive	than	GnRH	agonists,	and	










confirmed,	 iron	should	be	promptly	 initiated	to	reduce	symptoms.28 











A	promising	 class	of	 agents	 for	 the	 treatment	of	uterine	fibroids	 in	
pre-	menopausal	women	includes	aromatase	inhibitors	such	as	letro-
zole	and	anastrozole.	However,	at	this	time,	there	is	limited	evidence	
to	 support	 their	 broad	 and	 long-	term	 use	 for	 fibroids.	 Aromatase	
inhibitors	 such	 as	 letrozole	 (2.5	 or	 5	 mg	 orally	 once	 a	 day)	 and	
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anastrozole	(10	mg	orally	once	a	day)	induce	a	hypoestrogenic	state	
by	 inhibiting	 the	 aromatization	 of	 androgens	 to	 estrogens	 which	












UAE	 and	 MRgFUS	 are	 effective	 minimally	 invasive	 treatments	 for	
fibroids	in	women	who	decline	surgery	or	are	not	good	surgical	can-
didates.	These	outpatient	or	short	hospital	stay	procedures	have	the	






emic	 necrosis	 of	 the	 fibroids.31	Under	 light	 sedation,	 a	 small	 cathe-
ter	 is	 introduced	via	 the	 right	 common	 femoral	 artery	 to	 reach	 and	
embolize	 the	uterine	 arteries	bilaterally.32	This	procedure	 treats	 the	
whole	uterus,	rather	than	the	fibroids	specifically,	and	has	the	poten-
tial	of	permanently	impairing	uterine	and	ovarian	function.33 Current 
pregnancy,	 suspected	 cancer,	 and	 active	 pelvic	 infections	 are	 abso-
lute	 contraindications	 to	 this	 procedure.	 Women	 undergoing	 UAE	
reported	an	approximate	42%	fibroid	shrinkage	at	3	months,	shorter	
menstrual	duration	and	improvement	of	bulk	symptoms.17 Compared 
to	myomectomy	 or	 hysterectomy,	 UAE	 is	 a	 shorter	 procedure	with	
faster	recovery	and	quicker	return	to	normal	activities.17	However,	it	
is	associated	with	a	higher	rate	of	minor	complications	(5%),	including	




syndrome	caused	by	 the	 release	of	 ischemic	fibroid	products	 in	 the	
blood	stream	which	can	result	 in	severe	pain	and	fever	and	requires	
intense	analgesic	treatment	and	hydration.32
2.2.2 | Magnetic resonance guided focused 
radiofrequency ablation
MRgFUS,	 also	 known	 as	 high	 intensity	 focused	 ultrasound	 (HIFU),	
is	 an	 available	 but	 not	 largely	 adopted	 fibroid-	specific	 therapy	 that	
uses	high	intensity	transabdominal	ultrasound	waves	to	induce	fibroid	
coagulative	 necrosis	 and	 regression.33	 Because	 this	 procedure	 is	






improvement	 of	 symptoms	 at	 6	months.17,34	Although	 rare,	 revers-
ible	pelvic	neuropathy	and	 local	 skin	burns	are	 the	main	 risks	asso-
ciated	 with	 MRgFUS.	 For	 the	 latter	 reason,	 the	 procedure	 is	 not	
recommended	for	women	with	prior	extensive	abdominal/pelvic	sur-
geries	or	 abdominal	 scarring.	The	 rates	of	 re-	intervention	 following	
MRgFUS	are	higher	(30.5%)	compared	with	myomectomies	or	UAE.34 
Data	 on	 successful	 pregnancies	 after	 MRgFUS	 are	 rare	 and	 need	
further	investigation.34
2.3 | Surgical management
Surgical	 management	 options	 include	 myomectomies,	 hysterecto-












tions	 (1%–5%).36	The	most	common	complication	 is	high	 intrapro-
cedural	blood	loss,	for	which	intra-	fibroid	infiltration	of	vasopressin,	
intravaginal	 misoprostol	 or	 dinoprostone,	 the	 use	 of	 pro-	fibrin/
thrombin	 agents,	 or	 the	 use	 of	 tourniquet	 around	 the	 cervix	 or	
infundibulo-	pelvic	 ligaments	have	been	demonstrated	 to	decrease	




the	procedure	of	choice	 for	 the	 removal	of	smaller	 type	0	or	 type	
1	 submucosal	 fibroids.36	 Type,	 size,	 and	 number	 of	 fibroids	 have	
been	shown	to	predict	 the	 likelihood	of	achieving	complete	surgi-
cal	 resection	 and	 recurrence.17	 Laparoscopic	 myomectomy,	 when	
feasible,	should	be	the	standard	procedure	for	intramural	and	sub-
serosal	fibroids.	This	approach	 is	associated	with	 lower	blood	 loss	
and	morbidity,	 shorter	 hospital	 stay,	 and	 less	 post-	operative	 pain	










have	 not	 completed	 childbearing	 and/or	 who	 simply	 wish	 to	 retain	
their	uterus.	Following	hysterectomy,	the	majority	of	women	report	a	
significant	improvement	in	quality	of	life	and	symptomatology	as	early	











ber	 of	 complications,	 including	 a	 0.4%	 incidence	 of	 major	 compli-









77%	volume	reduction	at	6	months)	with	a	 relatively	 low	rate	of	 re-	
intervention	 (11%),	 shorter	 hospital	 stay,	 and	 lower	 blood	 loss	 com-
pared	to	laparoscopic	myomectomies.38	However,	there	is	still	limited	







cryotherapy	devices	 are	used	 to	 achieve	endometrial	 destruction.39 
Each	device	has	specific	criteria	and	recommendations	for	use	mainly	











age	 older	 than	 45	 years,	 higher	 parity,	 history	 of	 dysmenorrhea	 or	
concomitant	adenomyosis.39
3  | FUTURE DIRECTIONS AND  
DISCUSSIONS
Symptomatic	 uterine	 fibroids	 are	 associated	 with	 significant	 mor-




invasive,	 and	 surgical	 treatment	 options	 for	 women	 with	 uterine	
fibroids	that	can	help	tailor	 the	management	of	this	condition	to	a	
patient's	characteristics,	symptoms,	goals,	and	eligibility	for	therapy.
However,	 while	 some	 advances	 in	 research	 have	 broadened	 our	
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